Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Causes of primary adrenal insufficiency (Addison's disease)

INTRODUCTION

When Thomas Addison described the disease that now bears his name [1], bilateral adrenal destruction by tuberculosis was its most common cause. Now tuberculosis accounts for only 7 to 20 percent of cases; autoimmune disease is responsible for 70 to 90 percent, with the remainder being caused by other infectious diseases, replacement by metastatic cancer or lymphoma, adrenal hemorrhage or infarction, or drugs (table 1) [2-5]. Disseminated tuberculous or fungal infections are still a major cause of adrenal insufficiency in populations with a high prevalence of these diseases, but as tuberculosis has been better controlled, the overall incidence of Addison's disease has decreased [6]. The prevalence of Addison's disease in Western countries has been estimated at 35 to 60 per million, but three studies indicate it may be as high as 144 per million [7-9].

This topic will review the major causes of primary adrenal insufficiency. Rarer causes are discussed separately. The rarer diseases, such as adrenal leukodystrophy/adrenal myeloneuropathy, are mostly inherited disorders that present in infancy or childhood. (See "Adrenoleukodystrophy" and "Unusual causes of adrenal insufficiency".)

AUTOIMMUNE ADRENALITIS

Destruction of adrenal cortex — What long was termed "idiopathic" primary adrenal insufficiency is the result of an autoimmune process that destroys the adrenal cortex. There is evidence of both humoral and cell-mediated immune mechanisms directed at the adrenal cortex, often associated with autoimmune destruction of other endocrine glands (referred to as polyglandular autoimmune syndromes). Antibodies that react with several steroidogenic enzymes (most often 21-hydroxylase) and all three zones of the adrenal cortex are present in the serum of up to 86 percent of patients with autoimmune primary adrenal insufficiency (anti-21-OHase [9]), but only rarely in patients with other causes of adrenal insufficiency, or in normal subjects [9,10]. However, up to 10 percent of first-degree relatives of patients with autoimmune primary adrenal insufficiency express these antibodies and have an increased risk of developing adrenal insufficiency [10]. (See "Pathogenesis of autoimmune adrenal insufficiency".)

Sex differences — Patients with autoimmune adrenal insufficiency as part of one of the polyglandular autoimmune syndromes are predominately female (70 percent). In contrast, patients with isolated autoimmune adrenal insufficiency are predominately male (71 percent) during the first two decades of life, are equally male and female in the third decade, and are predominately female (81 percent) thereafter [11]. The explanation for these sex differences is unknown.

Early findings — The first evidence of autoimmune adrenal insufficiency is usually an increase in plasma renin activity in association with a normal or low serum aldosterone concentration, suggesting that the zona glomerulosa is involved initially [12,13]. Several months to years later, zona fasciculata dysfunction becomes evident, first by a decreasing serum cortisol response to corticotropin (ACTH) stimulation, later by increased basal serum ACTH concentrations, and finally by decreasing basal serum cortisol concentrations and symptoms [12,14].

                

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2014. | This topic last updated: Feb 1, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Addison T. On the Constitutional and Local Effects of Disease of the Suprarenal Capsules, Highley, London 1855.
  2. Irvine WJ, Barnes EW. Adrenocortical insufficiency. Clin Endocrinol Metab 1972; 1:549.
  3. Zelissen PM, Bast EJ, Croughs RJ. Associated autoimmunity in Addison's disease. J Autoimmun 1995; 8:121.
  4. Kasperlik-Zaluska AA, Migdalska B, Czarnocka B, et al. Association of Addison's disease with autoimmune disorders--a long-term observation of 180 patients. Postgrad Med J 1991; 67:984.
  5. Moreira AC, Martinez R, Castro M, Elias LL. Adrenocortical dysfunction in paracoccidioidomycosis: comparison between plasma beta-lipotrophin/adrenocorticotrophin levels and adrenocortical tests. Clin Endocrinol (Oxf) 1992; 36:545.
  6. Nomura K, Demura H, Saruta T. Addison's disease in Japan: characteristics and changes revealed in a nationwide survey. Intern Med 1994; 33:602.
  7. Willis AC, Vince FP. The prevalence of Addison's disease in Coventry, UK. Postgrad Med J 1997; 73:286.
  8. Laureti S, Vecchi L, Santeusanio F, Falorni A. Is the prevalence of Addison's disease underestimated? J Clin Endocrinol Metab 1999; 84:1762.
  9. Erichsen MM, Løvås K, Skinningsrud B, et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab 2009; 94:4882.
  10. Husebye ES, Løvås K. Immunology of Addison's disease and premature ovarian failure. Endocrinol Metab Clin North Am 2009; 38:389.
  11. Spinner MW, Blizzard RM, Childs B. Clinical and genetic heterogeneity in idiopathic Addison's disease and hypoparathyroidism. J Clin Endocrinol Metab 1968; 28:795.
  12. Betterle C, Scalici C, Presotto F, et al. The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J Endocrinol 1988; 117:467.
  13. Saenger P, Levine LS, Irvine WJ, et al. Progressive adrenal failure in polyglandular autoimmune disease. J Clin Endocrinol Metab 1982; 54:863.
  14. Ahonen P, Miettinen A, Perheentupa J. Adrenal and steroidal cell antibodies in patients with autoimmune polyglandular disease type I and risk of adrenocortical and ovarian failure. J Clin Endocrinol Metab 1987; 64:494.
  15. Baker PR, Nanduri P, Gottlieb PA, et al. Predicting the onset of Addison's disease: ACTH, renin, cortisol and 21-hydroxylase autoantibodies. Clin Endocrinol (Oxf) 2012; 76:617.
  16. Blizzard RM, Chee D, Davis W. The incidence of adrenal and other antibodies in the sera of patients with idiopathic adrenal insufficiency (Addison's disease). Clin Exp Immunol 1967; 2:19.
  17. McHardy-Young S, Lessof MH, Maisey MN. Serum TSH and thyroid antibody studies in Addison's disease. Clin Endocrinol (Oxf) 1972; 1:45.
  18. Nerup J. Addison's disease--clinical studies. A report fo 108 cases. Acta Endocrinol (Copenh) 1974; 76:127.
  19. Myhre AG, Undlien DE, Løvås K, et al. Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. J Clin Endocrinol Metab 2002; 87:618.
  20. Brewer KW, Parziale VS, Eisenbarth GS. Screening patients with insulin-dependent diabetes mellitus for adrenal insufficiency. N Engl J Med 1997; 337:202.
  21. Marks SD, Girgis R, Couch RM. Screening for adrenal antibodies in children with type 1 diabetes and autoimmune thyroid disease. Diabetes Care 2003; 26:3187.
  22. Yu L, Brewer KW, Gates S, et al. DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease. J Clin Endocrinol Metab 1999; 84:328.
  23. Triolo TM, Baschal EE, Armstrong TK, et al. Homozygosity of the polymorphism MICA5.1 identifies extreme risk of progression to overt adrenal insufficiency among 21-hydroxylase antibody-positive patients with type 1 diabetes. J Clin Endocrinol Metab 2009; 94:4517.
  24. Barker JM, Ide A, Hostetler C, et al. Endocrine and immunogenetic testing in individuals with type 1 diabetes and 21-hydroxylase autoantibodies: Addison's disease in a high-risk population. J Clin Endocrinol Metab 2005; 90:128.
  25. Elfström P, Montgomery SM, Kämpe O, et al. Risk of primary adrenal insufficiency in patients with celiac disease. J Clin Endocrinol Metab 2007; 92:3595.
  26. Myhre AG, Aarsetøy H, Undlien DE, et al. High frequency of coeliac disease among patients with autoimmune adrenocortical failure. Scand J Gastroenterol 2003; 38:511.
  27. Ahonen P, Myllärniemi S, Sipilä I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990; 322:1829.
  28. Neufeld M, Maclaren NK, Blizzard RM. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine (Baltimore) 1981; 60:355.
  29. Trence DL, Morley JE, Handwerger BS. Polyglandular autoimmune syndromes. Am J Med 1984; 77:107.
  30. Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med 2004; 350:2068.
  31. Scott HS, Heino M, Peterson P, et al. Common mutations in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients of different origins. Mol Endocrinol 1998; 12:1112.
  32. Nagamine K, Peterson P, Scott HS, et al. Positional cloning of the APECED gene. Nat Genet 1997; 17:393.
  33. Heino M, Scott HS, Chen Q, et al. Mutation analyses of North American APS-1 patients. Hum Mutat 1999; 13:69.
  34. Meloni A, Perniola R, Faà V, et al. Delineation of the molecular defects in the AIRE gene in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients from Southern Italy. J Clin Endocrinol Metab 2002; 87:841.
  35. Björses P, Aaltonen J, Horelli-Kuitunen N, et al. Gene defect behind APECED: a new clue to autoimmunity. Hum Mol Genet 1998; 7:1547.
  36. Gylling M, Tuomi T, Björses P, et al. ss-cell autoantibodies, human leukocyte antigen II alleles, and type 1 diabetes in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab 2000; 85:4434.
  37. DeVoss JJ, Anderson MS. Lessons on immune tolerance from the monogenic disease APS1. Curr Opin Genet Dev 2007; 17:193.
  38. Finnish-German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 1997; 17:399.
  39. Rosatelli MC, Meloni A, Meloni A, et al. A common mutation in Sardinian autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients. Hum Genet 1998; 103:428.
  40. Li Y, Song YH, Rais N, et al. Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism. J Clin Invest 1996; 97:910.
  41. Kifor O, McElduff A, LeBoff MS, et al. Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism. J Clin Endocrinol Metab 2004; 89:548.
  42. Söderbergh A, Myhre AG, Ekwall O, et al. Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2004; 89:557.
  43. Böckle BC, Wilhelm M, Müller H, et al. Oral mucous squamous cell carcinoma-an anticipated consequence of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). J Am Acad Dermatol 2010; 62:864.
  44. Chen S, Sawicka J, Betterle C, et al. Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison's disease, and premature ovarian failure. J Clin Endocrinol Metab 1996; 81:1871.
  45. Betterle C, Greggio NA, Volpato M. Clinical review 93: Autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 1998; 83:1049.
  46. Ekwall O, Hedstrand H, Grimelius L, et al. Identification of tryptophan hydroxylase as an intestinal autoantigen. Lancet 1998; 352:279.
  47. Högenauer C, Meyer RL, Netto GJ, et al. Malabsorption due to cholecystokinin deficiency in a patient with autoimmune polyglandular syndrome type I. N Engl J Med 2001; 344:270.
  48. Husebye ES, Gebre-Medhin G, Tuomi T, et al. Autoantibodies against aromatic L-amino acid decarboxylase in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 1997; 82:147.
  49. Dittmar M, Kahaly GJ. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab 2003; 88:2983.
  50. Ward L, Paquette J, Seidman E, et al. Severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in an adolescent girl with a novel AIRE mutation: response to immunosuppressive therapy. J Clin Endocrinol Metab 1999; 84:844.
  51. Asherson RA, Hughes GR. Recurrent deep vein thrombosis and Addison's disease in "primary" antiphospholipid syndrome. J Rheumatol 1989; 16:378.
  52. Tucker WS Jr, Niblack GD, McLean RH, et al. Serositis with autoimmune endocrinopathy: clinical and immunogenetic features. Medicine (Baltimore) 1987; 66:138.
  53. Kemp EH, Gawkrodger DJ, Watson PF, Weetman AP. Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA). Clin Exp Immunol 1998; 114:333.
  54. Guttman PH. Addison's disease. A statistical analysis of five hundred and sixty-six cases and a study of the pathology. Arch Pathol 1930; 10:742.
  55. Vita JA, Silverberg SJ, Goland RS, et al. Clinical clues to the cause of Addison's disease. Am J Med 1985; 78:461.
  56. Laureti S, Aubourg P, Calcinaro F, et al. Etiological diagnosis of primary adrenal insufficiency using an original flowchart of immune and biochemical markers. J Clin Endocrinol Metab 1998; 83:3163.
  57. Sun ZH, Nomura K, Toraya S, et al. Clinical significance of adrenal computed tomography in Addison's disease. Endocrinol Jpn 1992; 39:563.
  58. Villabona CM, Sahun M, Ricart W, et al. Tuberculous Addison's disease. Utility of CT in diagnosis and follow-up. Eur J Radiol 1993; 17:210.
  59. Guo YK, Yang ZG, Li Y, et al. Addison's disease due to adrenal tuberculosis: contrast-enhanced CT features and clinical duration correlation. Eur J Radiol 2007; 62:126.
  60. Penrice J, Nussey SS. Recovery of adrenocortical function following treatment of tuberculous Addison's disease. Postgrad Med J 1992; 68:204.
  61. Bhatia E, Jain SK, Gupta RK, Pandey R. Tuberculous Addison's disease: lack of normalization of adrenocortical function after anti-tuberculous chemotherapy. Clin Endocrinol (Oxf) 1998; 48:355.
  62. Gülmez I, Keleştimur F, Durak AC, Ozesmi M. Changes in the size of adrenal glands in acute pulmonary tuberculosis with therapy. Endocr J 1996; 43:573.
  63. Sarosi GA, Voth DW, Dahl BA, et al. Disseminated histoplasmosis: results of long-term follow-up. A center for disease control cooperative mycoses study. Ann Intern Med 1971; 75:511.
  64. Washburn RG, Bennett JE. Reversal of adrenal glucocorticoid dysfunction in a patient with disseminated histoplasmosis. Ann Intern Med 1989; 110:86.
  65. Abad A, Gomez I, Velez P, Restrepo A. Adrenal function in paracoccidioidomycosis: a prospective study in patients before and after ketoconazole therapy. Infection 1986; 14:22.
  66. Walker BF, Gunthel CJ, Bryan JA, et al. Disseminated cryptococcosis in an apparently normal host presenting as primary adrenal insufficiency: diagnosis by fine needle aspiration. Am J Med 1989; 86:715.
  67. MALONEY PJ. Addison's disease due to chronic disseminated coccidioidomycosis. AMA Arch Intern Med 1952; 90:869.
  68. ABERNATHY RS, MELBY JC. Addison's disease in North American blastomycosis. N Engl J Med 1962; 266:552.
  69. Heppner C, Petzke F, Arlt W, et al. Adrenocortical insufficiency in Rhodesian sleeping sickness is not attributable to suramin. Trans R Soc Trop Med Hyg 1995; 89:65.
  70. Blum JA, Schmid C, Hatz C, et al. Sleeping glands? - The role of endocrine disorders in sleeping sickness (T.b. gambiense Human African Trypanosomiasis). Acta Trop 2007; 104:16.
  71. Xarli VP, Steele AA, Davis PJ, et al. Adrenal hemorrhage in the adult. Medicine (Baltimore) 1978; 57:211.
  72. Rao RH, Vagnucci AH, Amico JA. Bilateral massive adrenal hemorrhage: early recognition and treatment. Ann Intern Med 1989; 110:227.
  73. Streeten DHP. Adrenal hemorrhage. Endocrinologist 1996; 6:277.
  74. Migeon CJ, Kenny FM, Hung W, Voorhess ML. Study of adrenal function in children with meningitis. Pediatrics 1967; 40:163.
  75. MARGARETTEN W, NAKAI H, LANDING BH. Septicemic adrenal hemorrhage. Am J Dis Child 1963; 105:346.
  76. Rosenberger LH, Smith PW, Sawyer RG, et al. Bilateral adrenal hemorrhage: the unrecognized cause of hemodynamic collapse associated with heparin-induced thrombocytopenia. Crit Care Med 2011; 39:833.
  77. Caron P, Chabannier MH, Cambus JP, et al. Definitive adrenal insufficiency due to bilateral adrenal hemorrhage and primary antiphospholipid syndrome. J Clin Endocrinol Metab 1998; 83:1437.
  78. Espinosa G, Santos E, Cervera R, et al. Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients. Medicine (Baltimore) 2003; 82:106.
  79. Kovacs KA, Lam YM, Pater JL. Bilateral massive adrenal hemorrhage. Assessment of putative risk factors by the case-control method. Medicine (Baltimore) 2001; 80:45.
  80. Cedermark BJ, Blumenson LE, Pickren JW, et al. Ths significance of metastases to the adrenal glands in adenocarcinoma of the colon and rectum. Surg Gynecol Obstet 1977; 144:537.
  81. Redman BG, Pazdur R, Zingas AP, Loredo R. Prospective evaluation of adrenal insufficiency in patients with adrenal metastasis. Cancer 1987; 60:103.
  82. Seidenwurm DJ, Elmer EB, Kaplan LM, et al. Metastases to the adrenal glands and the development of Addison's disease. Cancer 1984; 54:552.
  83. Serrano S, Tejedor L, Garcia B, et al. Addisonian crisis as the presenting feature of bilateral primary adrenal lymphoma. Cancer 1993; 71:4030.
  84. Huminer D, Garty M, Lapidot M, et al. Lymphoma presenting with adrenal insufficiency. Adrenal enlargement on computed tomographic scanning as a clue to diagnosis. Am J Med 1988; 84:169.
  85. Barker NW. The pathologic anatomy in twenty-eight cases of Addison's disease. Arch Pathol 1929; 8:432.
  86. Cedermark BJ, Sjöberg HE. The clinical significance of metastases to the adrenal glands. Surg Gynecol Obstet 1981; 152:607.
  87. Jabre P, Combes X, Lapostolle F, et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet 2009; 374:293.
  88. Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987; 317:812.
  89. Riedl M, Maier C, Zettinig G, et al. Long term control of hypercortisolism with fluconazole: case report and in vitro studies. Eur J Endocrinol 2006; 154:519.
  90. LIDDLE GW, ISLAND D, LANCE EM, HARRIS AP. Alterations of adrenal steroid patterns in man resulting from treatment with a chemical inhibitor of 11 beta-hydroxylation. J Clin Endocrinol Metab 1958; 18:906.
  91. Ashby H, DiMattina M, Linehan WM, et al. The inhibition of human adrenal steroidogenic enzyme activities by suramin. J Clin Endocrinol Metab 1989; 68:505.
  92. Stein CA, Saville W, Yarchoan R, et al. Suramin and function of the adrenal cortex. Ann Intern Med 1986; 104:286.
  93. Kobayashi K, Weiss RE, Vogelzang NJ, et al. Mineralocorticoid insufficiency due to suramin therapy. Cancer 1996; 78:2411.
  94. Elias AN, Gwinup G. Effects of some clinically encountered drugs on steroid synthesis and degradation. Metabolism 1980; 29:582.
  95. Keilholz U, Guthrie GP Jr. Adverse effect of phenytoin on mineralocorticoid replacement with fludrocortisone in adrenal insufficiency. Am J Med Sci 1986; 291:280.
  96. Kyriazopoulou V, Parparousi O, Vagenakis AG. Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. J Clin Endocrinol Metab 1984; 59:1204.
  97. Ediger SK, Isley WL. Rifampicin-induced adrenal insufficiency in the acquired immunodeficiency syndrome: difficulties in diagnosis and treatment. Postgrad Med J 1988; 64:405.
  98. Robinson BG, Hales IB, Henniker AJ, et al. The effect of o,p'-DDD on adrenal steroid replacement therapy requirements. Clin Endocrinol (Oxf) 1987; 27:437.
  99. Mackenzie JS, Burrows L, Burchard KW. Transient hypoadrenalism during surgical critical illness. Arch Surg 1998; 133:199.
  100. Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med 2004; 350:1629.